Combination of Eribulin and Anlotinib Exerts Synergistic Cytotoxicity in Retroperitoneal Liposarcoma by Inducing Endoplasmic Reticulum Stress
Primary retroperitoneal liposarcoma (RLPS) is a rare heterogeneous tumor occurring within retroperitoneal space, and its overall survival did not improve much in the past few decades. Based on a small-sample clinical practice at our center, patients with RLPS can greatly benefit from combination of anlotinib and eribulin. In this study, we investigated combinational effect of anlotinib and eribulin on RLPS. Through transcriptome analysis, we uncovered and validated that synergistic effect mainly induced by endoplasmic reticulum stress (ERS) pathway both in vitro and in vivo. Overall design: To elucidate the underlying mechanisms by which combination of anlotinib and eribulin inhibited RLPS cells, RNA-seq was conducted to evaluate transcriptome changes in RLPS cells after being treated with optimal concentration which could elicit maximum synergy effect. 93T449, 94T778 and sw872 cell lines were used in this study.